| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | M6S1; NPP1; NPPS; PC-1; PCA1; ARHR2; COLED; PDNP1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human ENPP1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ENPP1抗体的模拟参考文献示例(注：部分文献为假设性示例，实际文献需通过学术数据库检索获取)：
1. **文献名称**：*Therapeutic targeting of ENPP1 with monoclonal antibodies in metastatic cancer*
**作者**：Smith A, et al.
**摘要**：研究开发了一种靶向ENPP1的单克隆抗体，通过抑制其酶活性减少细胞外cGAMP水解，增强STING通路抗肿瘤免疫反应，显著抑制小鼠模型中肿瘤转移。
2. **文献名称**：*ENPP1 inhibition via antibody blockade prevents vascular calcification in chronic kidney disease*
**作者**：Chen L, et al.
**摘要**：报道了一种特异性抗ENPP1抗体，在慢性肾病模型中有效阻断其焦磷酸酶活性，减少血管钙化，为治疗异位钙化提供新策略。
3. **文献名称**：*Development of a high-affinity anti-ENPP1 antibody for immunohistochemical detection in breast cancer tissues*
**作者**：Rodriguez M, et al.
**摘要**：研究成功制备了一种高灵敏度兔源多克隆抗体，用于乳腺癌组织ENPP1蛋白表达的免疫组化检测，验证其与肿瘤微环境调控的相关性。
4. **文献名称**：*Autoantibodies against ENPP1 in patients with autoimmune hypophosphatemic rickets*
**作者**：Tanaka K, et al.
**摘要**：首次在自身免疫性低磷佝偻病患者血清中发现抗ENPP1自身抗体，揭示其可能通过干扰ENPP1功能导致磷酸盐代谢异常。
**备注**：以上为模拟示例，实际文献建议通过PubMed、Web of Science等平台，以关键词“ENPP1 antibody”“anti-ENPP1 therapy”“ENPP1 autoantibody”检索近年研究。
ENPP1 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 1) is a transmembrane enzyme that hydrolyzes extracellular nucleotides like ATP and AMP, generating inorganic pyrophosphate (PPi), a key regulator of bone mineralization and soft tissue calcification. It plays roles in phosphate metabolism, insulin signaling, and immune modulation. ENPP1 antibodies are tools used to study its expression, function, and involvement in diseases.
Mutations in ENPP1 are linked to rare genetic disorders, including autosomal recessive hypophosphatemic rickets (ARHR2) and generalized arterial calcification of infancy (GACI). ENPP1 dysregulation is also implicated in metabolic syndromes, cancer progression, and pathological calcification. Antibodies targeting ENPP1 help detect protein levels in tissues or fluids via techniques like Western blot, immunohistochemistry, or flow cytometry, aiding research on disease mechanisms.
Therapeutic anti-ENPP1 antibodies are under exploration for conditions like tumor immunotherapy, as ENPP1 overexpression in cancers suppresses anti-tumor immunity by degrading extracellular ATP, a pro-inflammatory signal. Conversely, recombinant ENPP1 or enzyme replacement strategies are being tested for ENPP1-deficient disorders. Thus, ENPP1 antibodies serve both diagnostic and therapeutic roles in understanding and managing calcification-related and metabolic diseases.
×
